Assessing residual inflammation and macrophage presence in lupus nephritis after 3 months of intensified treatment with prednisolone, mycofenolate mofetil and voclosporin as compared to mycofenolate mofetil and prednisolone: an open label randomized controlled trial (MAPLE study)

Start Date23 Apr 2026

Sponsor / Collaborator-

NCT07611214

/ RecruitingPhase 4

PRESERVE: A Multi-Center Phase 4 Study of the Efficacy and Safety of LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab at Inducing Rapid Renal Response in Patients With Lupus Nephritis

The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).

Start Date22 Apr 2026

Sponsor / Collaborator

Aurinia Pharmaceuticals, Inc.

JPRN-jRCTs041250131

/ RecruitingPhase 4

A study on the effects of voclosporin on RNA expression levels in peripheral immune cells of patients with lupus nephritis using single-cell RNA sequencing analysis

Start Date01 Dec 2025

Sponsor / Collaborator-

100 Clinical Results associated with Voclosporin

100 Translational Medicine associated with Voclosporin

100 Patents (Medical) associated with Voclosporin

136

Literatures (Medical) associated with Voclosporin

01 Jun 2026·CURRENT OPINION IN IMMUNOLOGY

New developments and future directions in the management of systemic lupus erythematosus

Review

Author: Kirou, Raphael A ; Kirou, Kyriakos A ; Flouda, Sofia

Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder with a pathogenesis that includes aberrant interactions between the innate and adaptive immune systems. Dominant pathogenetic axes include the type I interferon pathway and loss of tolerance in B cell/plasma cell development with autoantibody formation. The disease is clinically and pathogenetically heterogeneous, which has hampered the conduct of clinical trials and the development of novel therapies. Nevertheless, since the 2011 Food and Drug Administration (FDA) approval of belimumab for SLE, there has been an explosion of clinical trials that has led to the approval of anifrolumab for SLE as well as belimumab, voclosporin, and obinutuzumab for lupus nephritis. At the same time, multiple drugs with important new targets have progressed through phase 1-3 clinical trials, promising improved outcomes. In this review, we focus on new and emerging treatments over the last few years and discuss their potential impact on developing new directions in lupus management.

22 Apr 2026·Cureus Journal of Medical Science

The Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis

Article

Author: Koirala, Abbal ; Azar, Antoine ; Mener, Andrew ; Timlin, Homa ; Geetha, Duruvu

Achieving remission or low disease activity in systemic lupus erythematosus reduces long-term organ damage, disease flares, and corticosteroid exposure. Kidney involvement from lupus nephritis is often progressive and associated with adverse long-term outcomes. Early, effective immunosuppression during the active inflammatory phase of lupus nephritis is linked to improved renal outcomes. Although voclosporin and obinutuzumab have each demonstrated efficacy in lupus nephritis, real-world data on their combined use remain limited. Here, we report outcomes in three patients with active lupus nephritis who were treated with both Food and Drug Administration (FDA)-approved agents.

20 Mar 2026·Cureus Journal of Medical Science

Rapid Reduction in Proteinuria With the Initiation of Voclosporin in Lupus Nephritis: A Single-Center Experience

Article

Author: Atta, Mohamed G ; Geetha, Duvuru ; Ahn, Boyoung ; Timlin, Homa ; Kaniecki, Timothy ; Kamel, Ihab ; Ong, Johnson

Background and purpose Lupus nephritis (LN) is a severe, life-threatening complication of systemic lupus erythematosus (SLE). Reduction in proteinuria is strongly associated with long‑term renal outcomes and is a key endpoint in LN clinical trials. Early initiation of immunosuppressive therapy improves renal recovery, and a rapid decline in proteinuria correlates with achieving remission at 12 months. Voclosporin may cause a mild, early decline in estimated glomerular filtration rate (eGFR) due to hemodynamic effects, which typically stabilizes with continued therapy. This study evaluated the effect of voclosporin on early (≤12‑week) proteinuria reduction and its tolerability when used in combination with standard immunosuppressive therapy in patients with biopsy‑proven LN. Methods We conducted a retrospective cohort study using the institutional review board-approved Epic Lupus Database at Johns Hopkins Bayview Medical Center, Baltimore, MD, USA. Patients were included if they had biopsy‑confirmed LN and received voclosporin. Demographics, clinical characteristics, and immunosuppressive regimens were abstracted from electronic medical records. Relative changes in urine protein creatinine ratio (UPCR) from baseline to four, eight, and 12 weeks were calculated with corresponding 95% confidence intervals (CIs). Results Twenty‑five patients with biopsy‑proven LN were treated with voclosporin; all received concurrent hydroxychloroquine and tolerated voclosporin without discontinuation. Most patients were treated with mycophenolate or mycophenolic acid (92%) and corticosteroids (96%; median prednisone‑equivalent dose 15 mg/day). Relative reductions in UPCR from baseline were observed at four weeks (-0.27; 95% CI, -0.49 to -0.05), eight weeks (-0.51; 95% CI, -0.65 to -0.37), and 12 weeks (-0.57; 95% CI, -0.71 to -0.43). No statistically significant change in eGFR was observed over the 12‑week treatment period. Conclusion Initiation of voclosporin in combination with standard immunosuppressive therapy in biopsy‑proven LN was associated with early improvement in renal activity, as reflected by significant reductions in UPCR beginning at four weeks. To our knowledge, this represents the largest case series to date describing early real‑world outcomes with voclosporin in LN. Given that persistent proteinuria may indicate ongoing renal inflammation and/or chronic damage, these findings support consideration of voclosporin as a first‑line therapeutic option for active LN.

184

News (Medical) associated with Voclosporin

06 Jul 2026

·www.businesswire.com

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS® and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study’s primary endpoint is the proportion of patients achieving complete renal response (CRR) at 6 months. LUPKYNIS is the only FDA-approved oral therapy for lupus nephritis and the only treatment for lupus nephritis that has shown a statistically significant increase in CRR after 6 months of therapy. Belimumab is a B cell-activating factor (BAFF) inhibitor indicated for the treatment of both systemic lupus erythematosus (SLE) and lupus nephritis. Obinutuzumab is a CD20-directed cytolytic antibody indicated for the treatment of lupus nephritis. Anifrolumab is a type 1 interferon receptor antagonist indicated for the treatment of SLE. “As underscored by the recently published American College of Rheumatology guidelines for the treatment of lupus nephritis, the goal of treatment should be to arrest proteinuria, which is the hallmark sign of ongoing kidney damage, as quickly as possible,” commented Anca Askanase, MD, MPH, Chair of the Department of Medicine and Chief of the Division of Rheumatology at Hospital for Special Surgery and Co-Lead Investigator of PRESERVE. “Unfortunately, even with the newer agents approved in the past few years, the majority of patients do not achieve CRR by 6 months, and many do not achieve CRR even by 12 months.” “There is great mechanistic rationale in combining LUPKYNIS with these biologic agents to improve outcomes,” commented Arvind Madan, MD, Physician and Principal Investigator of the Research Division at Central Florida Kidney Specialists and Co-Lead Investigator of PRESERVE. “LUPKYNIS protects the kidneys by directly stabilizing podocytes and inhibiting T cell activation, belimumab and obinutuzumab inhibit B cell activation, and anifrolumab blocks type 1 interferon signaling. By taking a multitarget therapeutic approach that intervenes in non-redundant biological pathways, each of which independently contribute to nephron loss, there is the potential to stop nephron damage more rapidly in the short term and preserve more kidney function in the long term.” About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Forward-Looking Statements This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with the conduct, timing and results of clinical studies and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com.

Drug ApprovalPhase 3Phase 2

04 Jun 2026

·www.biospace.com

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

— New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress — ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS ® in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress ( EULAR 2026 Presentation ). This new analysis on the safety population of 356 patients (178 on LUPKYNIS and 178 on placebo) indicates that LUPKYNIS was associated with a statistically significant 53% reduction in the risk of renal-related event or death (hazard ratio=0.47; p=0.0007). Hazard ratios (HRs) favored treatment with LUPKYNIS for the following individual components of the composite endpoint: death (HR=0.19 [an 81% reduction in risk]; p=0.0929), treatment failure (HR=0.45 [a 55% reduction in risk]; p=0.0062) and worsening proteinuria (HR=0.22 [a 78% reduction in risk]; p<0.0001). “This new time-to-event analysis demonstrates LUPKYNIS’ favorable effect on clinically important outcomes in lupus nephritis patients,” commented Amit Saxena, MD, Associate Professor of Medicine, NYU Grossman School of Medicine Division of Rheumatology and lead author of the EULAR presentation. “LUPKYNIS is the only treatment that has demonstrated a statistically significant improvement in complete renal response (CRR) in as short as 6 months in a randomized Phase 3 clinical study. These new results further characterize the benefits that LUPKYNIS can bring to patients suffering from lupus nephritis.” About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Contacts Investor Inquiries: ir@auriniapharma.com

07 May 2026

·www.businesswire.com

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three months ended March 31, 2026, total revenue was $77.7 million, up 24% from $62.5 million in the same period of 2025. Net Product Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $73.6 million, up 23% from $60.0 million in the same period of 2025. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2026, license, collaboration and royalty revenue from Aurinia’s collaboration partner, Otsuka, was $4.1 million, up 64% from $2.5 million in the same period of 2025. Net Product Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $73.6 million, up 23% from $60.0 million in the same period of 2025. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2026, license, collaboration and royalty revenue from Aurinia’s collaboration partner, Otsuka, was $4.1 million, up 64% from $2.5 million in the same period of 2025. Net Income: For the three months ended March 31, 2026, net income was $34.4 million, up 48% from $23.3 million in the same period of 2025. Diluted Earnings per Share: For the three months ended March 31, 2026, diluted earnings per share was $0.25, up 56% from $0.16 in the same period of 2025. Cash Flows from Operating Activities: For the three months ended March 31, 2026, cash flows from operating activities were $32.6 million, up 2408% from $1.3 million in the same period of 2025. Cash Position As of March 31, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $378.8 million, compared to $398.0 million at December 31, 2025. For the three months ended March 31, 2026, cash outflows from financing activities were $53.7 million, which included the repurchase of 2.5 million of the Company’s common shares for $36.2 million and tax withholding payments related to net settlements of equity awards of $14.6 million. 2026 Total Revenue and Net Product Sales Guidance Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net product sales of $305 million to $315 million, up 12% to 16% compared to 2025. “Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases,” stated Kevin Tang, Chief Executive Officer. “LUPKYNIS is emerging as a standard-of-care treatment for lupus nephritis, and aritinercept, now in clinical development for three potential indications, has therapeutic potential across a wide range of autoimmune disorders.” About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Forward-Looking Statements This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com. AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) March 31, 2026 December 31, 2025 (Unaudited) ASSETS Current assets: Cash, cash equivalents and restricted cash $ 41,008 $ 80,213 Short-term investments 337,775 317,784 Accounts receivable, net 49,175 41,454 Inventory 46,410 45,690 Prepaid expenses and deposits 4,119 5,746 Other current assets 1,757 1,080 Total current assets 480,244 491,967 Deferred tax assets, net 166,917 176,194 Finance right-of-use lease assets 69,508 73,865 Intangible assets, net 3,590 3,761 Operating right-of-use lease assets 1,659 3,596 Property and equipment, net 1,986 2,111 Other noncurrent assets 93 93 Total assets $ 723,997 $ 751,587 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,661 $ 3,313 Accrued expenses 58,196 66,621 Finance lease liabilities, current portion 16,519 16,523 Deferred revenue 5,036 3,720 Operating lease liabilities, current portion 1,622 1,067 Other current liabilities 2,522 2,480 Total current liabilities 86,556 93,724 Finance lease liabilities, less current portion 48,181 52,322 Deferred revenue, less current portion 12,413 12,648 Deferred compensation and other noncurrent liabilities 6,903 6,662 Operating lease liabilities, less current portion 2,318 4,900 Total liabilities 156,371 170,256 Shareholders' equity Common shares — no par value, unlimited shares authorized, 130,771 and 132,323 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 1,086,650 1,120,035 Additional paid-in capital 96,869 111,263 Accumulated other comprehensive loss (880 ) (599 ) Accumulated deficit (615,013 ) (649,368 ) Total shareholders' equity 567,626 581,331 Total liabilities and shareholders' equity $ 723,997 $ 751,587 AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (in thousands, except per share data) Three Months Ended March 31, 2026 2025 Revenue Net product sales $ 73,563 $ 59,971 License, collaboration and royalty revenue 4,142 2,494 Total revenue 77,705 62,465 Operating expenses Cost of revenue 6,505 8,574 Selling, general and administrative 22,029 20,339 Research and development 7,470 5,743 Restructuring — 1,533 Other expense, net 279 4,429 Total operating expenses 36,283 40,618 Income from operations 41,422 21,847 Interest income 3,515 3,569 Interest expense (1,012 ) (1,067 ) Net income before income taxes 43,925 24,349 Income tax expense 9,570 1,005 Net income $ 34,355 $ 23,344 Earnings per share Basic $ 0.26 $ 0.17 Diluted $ 0.25 $ 0.16 Shares used in computing earnings per share Basic 132,375 138,917 Diluted 137,639 143,199 AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (in thousands) Three Months Ended March 31, 2026 2025 Cash flows from operating activities: Net income $ 34,355 $ 23,344 Adjustments to reconcile net income to cash flows from operating activities: Deferred income tax 9,277 — Share-based compensation (866 ) (3,409 ) Amortization and depreciation 4,816 4,856 Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability (416 ) 1,812 Net amortization of premiums and discounts on investments (2,319 ) (2,656 ) Other, net 581 2,325 Net changes in operating assets and liabilities: Accounts receivable, net (7,721 ) (3,806 ) Inventory (720 ) (6,967 ) Prepaid expenses and other current assets 950 6,033 Accounts payable (652 ) (974 ) Accrued expenses and other liabilities (5,592 ) (23,405 ) Deferred revenue 1,081 4,342 Operating lease liabilities (214 ) (195 ) Cash flows from operating activities 32,560 1,300 Cash flows from investing activities: Proceeds from the sale and maturities of investments 109,000 123,035 Purchases of investments (127,041 ) (91,986 ) Purchases of property, equipment and intangible assets (39 ) (17 ) Cash flows from investing activities (18,080 ) 31,032 Cash flows from financing activities: Purchase of common shares under Share Repurchase Plan (36,165 ) (46,921 ) Payments of principal portion of Monoplant finance lease liability (3,653 ) (2,771 ) Proceeds from issuance of common shares for equity awards 713 9,288 Tax withholding payments related to net settlements of equity awards (14,580 ) (8,933 ) Cash flows from financing activities (53,685 ) (49,337 ) Net decrease in cash, cash equivalents and restricted cash (39,205 ) (17,005 ) Cash, cash equivalents and restricted cash, beginning of the period 80,213 83,433 Cash, cash equivalents and restricted cash, end of the period $ 41,008 $ 66,428

100 Deals associated with Voclosporin

External Link

KEGG	Wiki	ATC	Drug Bank
D09033	Voclosporin	L04AD03	DB11693

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lupus Nephritis	United States	Aurinia Pharmaceuticals, Inc.	22 Jan 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-infectious posterior uveitis	NDA/BLA	European Union	Lux Biosciences, Inc.	10 Feb 2010
Dry Eye Syndromes	Phase 3	United States	Aurinia Pharmaceuticals, Inc.	14 Oct 2019
Kerato conjunctivitis sicca	Phase 3	United States	Aurinia Pharmaceuticals, Inc.	14 Oct 2019
Acute rejection of renal transplant	Phase 3	-	Aurinia Pharmaceuticals, Inc.	01 Mar 2013
Uveitis	Phase 3	United States	Lux Biosciences, Inc.	01 Feb 2011
Uveitis	Phase 3	Austria	Lux Biosciences, Inc.	01 Feb 2011
Uveitis	Phase 3	Brazil	Lux Biosciences, Inc.	01 Feb 2011
Uveitis	Phase 3	Canada	Lux Biosciences, Inc.	01 Feb 2011
Uveitis	Phase 3	Czechia	Lux Biosciences, Inc.	01 Feb 2011
Uveitis	Phase 3	France	Lux Biosciences, Inc.	01 Feb 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2026	Not Applicable	Lupus Nephritis	77	Voclosporin 23.7 mg twice daily + mycophenolate mofetil 1 g twice daily	uqhzdbsrqw(htvjohtbke) = kesnnakumn aariwwagbe (ryikegqdrz ) View more	Positive	11 Jun 2026
				Voclosporin 23.7 mg twice daily + mycophenolate mofetil 1 g twice daily (difficult-to-treat patients)	qarrqqghhd(ccpqyesbac) = ikrydwcfoc dgqvipbnak (cxplvihbfs ) View more
NCT03021499 (AURORA 1, EULAR2026)	Phase 3	Lupus Nephritis	356	Voclosporin	oqzrhfffwq(fymahbivxe) = hcfshbslyb rlymewlcnt (cpinyfjbdq )	Positive	11 Jun 2026
				Placebo	oqzrhfffwq(fymahbivxe) = jbcnzufylh rlymewlcnt (cpinyfjbdq )
EULAR2026	Not Applicable	Lupus Nephritis	66	Combination immunosuppressive therapy	irxfljmgxv(peyurnhrbs) = qogswdytoa foeeypgpls (hsujovufwt ) View more	Positive	11 Jun 2026
ASN2025	Not Applicable	Lupus Nephritis	19	Voclosporin (Lupus Nephritis)	lzpxpoerfb(tavytuukhz) = gfkgpefjzl agkswdjmxf (sepimvjywn ) View more	Positive	08 Nov 2025
NCT05306873 (DIVERT, CTgov)	Phase 2	Systemic Lupus Erythematosus	12	MMF (Stage 2 MMF)	ttrnviookh = xdakrkjclt hbkkiktlaq (pcfgygtroo, vyysduxttd - bgbfcaehmn) View more	-	09 Sep 2025
				MMF (Stage 2 Placebo for MMF)	ttrnviookh = peieaelbjt hbkkiktlaq (pcfgygtroo, cthbulvvli - faajolfnqp) View more
ERA2025	Not Applicable	Lupus Nephritis \| Systemic Lupus Erythematosus	4	CyclophosphamideVoclosporinRituximabMethylprednisolone + CyclophosphamideVoclosporinRituximabMethylprednisolone + CyclophosphamideVoclosporinRituximabMethylprednisolone + CyclophosphamideVoclosporinRituximabMethylprednisolone	sfbkcmkekd(hifyocgckt) = bohxsdejtb qglorjivzw (aoeibzxcds ) View more	Positive	04 Jun 2025
AURORA 1 (ACR2024)	Phase 3	Lupus Nephritis	357	Voclosporin 23.7 mg BID	jfppmzniky(gozczrlmxq) = grizdovmsb sfvoigfnvs (rwzndkisve )	Positive	10 Nov 2024
				Placebo	jfppmzniky(gozczrlmxq) = bewljtbkyb sfvoigfnvs (rwzndkisve )
AURA-LV (ERA2024)	Phase 2/3	Lupus Nephritis	358	Voclosporin 23.7 mg BID + MMF (target 2 g/day) + oral GCs (25 mg/day)	svervzhyrv(mziqdspyvh) = The overall incidence of adverse events (AEs) was higher in IVC- and MMF-treated participants of ALMS, although more participants in AURA-LV and AURORA 1 reported hypertension and anemia. vlogvubevl (padkyxbmug ) View more	Positive	23 May 2024
				MMF (target 3 g/day) or IVC (0.5 to 1.0 g/m2/month × 6) + oral GCs
NCT03021499 (AURORA, Biospace) Manual	Not Applicable	Lupus Nephritis	-	LUPKYNIS	kcbcxofdxt(llgqgnfwsb) = eqrpawfjll otmjkaxpzx (eovpqhgnks )	Positive	09 May 2024
NCT03021499 (AURORA, Biospace) Manual	Not Applicable	Lupus Nephritis	25	LUPKYNIS, MMF, and steroids	ghbjuodxas(fcwkfoynsc) = bbvvulofjz bxjizgkpmw (eraealdzja )	Positive	09 May 2024
				MMF and glucocorticoids	ghbjuodxas(fcwkfoynsc) = mzsvvgmwfm bxjizgkpmw (eraealdzja )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis